The Experts below are selected from a list of 1011 Experts worldwide ranked by ideXlab platform
Hanneke Ijsselstijn - One of the best experts on this subject based on the ideXlab platform.
-
paediatric gastrointestinal endoscopy european society for paediatric gastroenterology hepatology and nutrition and european society of gastrointestinal endoscopy guidelines
2017Co-Authors: Mike Thomson, Cesare Hassan, Andrea Tringali, Jeanmarc Dumonceau, Marta Tavares, Merit M Tabbers, Raoul I Furlano, Manon C W Spaander, Christos Tzvinikos, Hanneke IjsselstijnAbstract:This guideline refers to infants, children, and adolescents ages 0 to 18 years. The areas covered include indications for diagnostic and therapeutic esophagogastroduodenoscopy and Ileocolonoscopy; endoscopy for foreign body ingestion; corrosive ingestion and stricture/stenosis endoscopic management; upper and lower gastrointestinal bleeding; endoscopic retrograde cholangiopancreatography; and endoscopic ultrasonography. Percutaneous endoscopic gastrostomy and endoscopy specific to inflammatory bowel disease has been dealt with in other guidelines and are therefore not mentioned in this guideline. Training and ongoing skill maintenance are to be dealt with in an imminent sister publication to this.
-
pediatric gastrointestinal endoscopy european society of gastrointestinal endoscopy esge and european society for paediatric gastroenterology hepatology and nutrition espghan guideline executive summary
2016Co-Authors: Andrea Tringali, Mike Thomson, Cesare Hassan, Jeanmarc Dumonceau, Marta Tavares, Merit M Tabbers, Raoul I Furlano, Manon C W Spaander, Christos Tzvinikos, Hanneke IjsselstijnAbstract:This Executive summary of the Guideline on pediatric gastrointestinal endoscopy from the European Society of Gastrointestinal Endoscopy (ESGE) and the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) refers to infants, children, and adolescents aged 0 – 18 years. The areas covered include: indications for diagnostic and therapeutic esophagogastroduodenoscopy and Ileocolonoscopy; endoscopy for foreign body ingestion; endoscopic management of corrosive ingestion and stricture/stenosis; upper and lower gastrointestinal bleeding; endoscopic retrograde cholangiopancreatography, and endoscopic ultrasonography. Percutaneous endoscopic gastrostomy and endoscopy specific to inflammatory bowel disease (IBD) have been dealt with in other Guidelines and are therefore not mentioned in this Guideline. Training and ongoing skill maintenance will be addressed in an imminent sister publication.
Mike Thomson - One of the best experts on this subject based on the ideXlab platform.
-
paediatric gastrointestinal endoscopy european society for paediatric gastroenterology hepatology and nutrition and european society of gastrointestinal endoscopy guidelines
2017Co-Authors: Mike Thomson, Cesare Hassan, Andrea Tringali, Jeanmarc Dumonceau, Marta Tavares, Merit M Tabbers, Raoul I Furlano, Manon C W Spaander, Christos Tzvinikos, Hanneke IjsselstijnAbstract:This guideline refers to infants, children, and adolescents ages 0 to 18 years. The areas covered include indications for diagnostic and therapeutic esophagogastroduodenoscopy and Ileocolonoscopy; endoscopy for foreign body ingestion; corrosive ingestion and stricture/stenosis endoscopic management; upper and lower gastrointestinal bleeding; endoscopic retrograde cholangiopancreatography; and endoscopic ultrasonography. Percutaneous endoscopic gastrostomy and endoscopy specific to inflammatory bowel disease has been dealt with in other guidelines and are therefore not mentioned in this guideline. Training and ongoing skill maintenance are to be dealt with in an imminent sister publication to this.
-
pediatric gastrointestinal endoscopy european society of gastrointestinal endoscopy esge and european society for paediatric gastroenterology hepatology and nutrition espghan guideline executive summary
2016Co-Authors: Andrea Tringali, Mike Thomson, Cesare Hassan, Jeanmarc Dumonceau, Marta Tavares, Merit M Tabbers, Raoul I Furlano, Manon C W Spaander, Christos Tzvinikos, Hanneke IjsselstijnAbstract:This Executive summary of the Guideline on pediatric gastrointestinal endoscopy from the European Society of Gastrointestinal Endoscopy (ESGE) and the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) refers to infants, children, and adolescents aged 0 – 18 years. The areas covered include: indications for diagnostic and therapeutic esophagogastroduodenoscopy and Ileocolonoscopy; endoscopy for foreign body ingestion; endoscopic management of corrosive ingestion and stricture/stenosis; upper and lower gastrointestinal bleeding; endoscopic retrograde cholangiopancreatography, and endoscopic ultrasonography. Percutaneous endoscopic gastrostomy and endoscopy specific to inflammatory bowel disease (IBD) have been dealt with in other Guidelines and are therefore not mentioned in this Guideline. Training and ongoing skill maintenance will be addressed in an imminent sister publication.
-
acquisition of competence in paediatric Ileocolonoscopy with virtual endoscopy training
2006Co-Authors: Mike Thomson, Robert Heuschkel, Nora Donaldson, Simon Murch, Rupert HindsAbstract:This study prospectively compared the rates of skill acquisition in Ileocolonoscopy in 2 consecutive groups of trainees in paediatric gastroenterology, with 1 cohort exposed to virtual endoscopy. All paediatric gastroenterology trainees rotating through our department during a 7-year period between 1997 and 2004 were formally assessed while performing ileocolonoscopies using a trainer case-by-case method. Fourteen consecutive trainees with no previous experience of Ileocolonoscopy were assessed. Comparison of rates of skill acquisition and lesion recognition using multiple linear regressions revealed a significant acceleration of achievement of endoscopic goals (P < 0.0001) in the group with prior exposure to virtual endoscopy.
Cesare Hassan - One of the best experts on this subject based on the ideXlab platform.
-
paediatric gastrointestinal endoscopy european society for paediatric gastroenterology hepatology and nutrition and european society of gastrointestinal endoscopy guidelines
2017Co-Authors: Mike Thomson, Cesare Hassan, Andrea Tringali, Jeanmarc Dumonceau, Marta Tavares, Merit M Tabbers, Raoul I Furlano, Manon C W Spaander, Christos Tzvinikos, Hanneke IjsselstijnAbstract:This guideline refers to infants, children, and adolescents ages 0 to 18 years. The areas covered include indications for diagnostic and therapeutic esophagogastroduodenoscopy and Ileocolonoscopy; endoscopy for foreign body ingestion; corrosive ingestion and stricture/stenosis endoscopic management; upper and lower gastrointestinal bleeding; endoscopic retrograde cholangiopancreatography; and endoscopic ultrasonography. Percutaneous endoscopic gastrostomy and endoscopy specific to inflammatory bowel disease has been dealt with in other guidelines and are therefore not mentioned in this guideline. Training and ongoing skill maintenance are to be dealt with in an imminent sister publication to this.
-
pediatric gastrointestinal endoscopy european society of gastrointestinal endoscopy esge and european society for paediatric gastroenterology hepatology and nutrition espghan guideline executive summary
2016Co-Authors: Andrea Tringali, Mike Thomson, Cesare Hassan, Jeanmarc Dumonceau, Marta Tavares, Merit M Tabbers, Raoul I Furlano, Manon C W Spaander, Christos Tzvinikos, Hanneke IjsselstijnAbstract:This Executive summary of the Guideline on pediatric gastrointestinal endoscopy from the European Society of Gastrointestinal Endoscopy (ESGE) and the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) refers to infants, children, and adolescents aged 0 – 18 years. The areas covered include: indications for diagnostic and therapeutic esophagogastroduodenoscopy and Ileocolonoscopy; endoscopy for foreign body ingestion; endoscopic management of corrosive ingestion and stricture/stenosis; upper and lower gastrointestinal bleeding; endoscopic retrograde cholangiopancreatography, and endoscopic ultrasonography. Percutaneous endoscopic gastrostomy and endoscopy specific to inflammatory bowel disease (IBD) have been dealt with in other Guidelines and are therefore not mentioned in this Guideline. Training and ongoing skill maintenance will be addressed in an imminent sister publication.
-
colon capsule endoscopy compared with other modalities in the evaluation of pediatric crohn s disease of the small bowel and colon
2016Co-Authors: Salvatore Oliva, S Cucchiara, Fortunata Civitelli, Emanuele Casciani, Giovanni Di Nardo, Cesare Hassan, Paola Papoff, Stanley A CohenAbstract:Background and Aims Data on colon capsule endoscopy (CCE) in evaluating the small bowel and colon concurrently are rare. This study aimed to evaluate the accuracy of CCE in assessing disease activity of the small bowel and colon in pediatric Crohn's disease (CD) by comparison with magnetic resonance enterography (MRE), small-intestine contrast US (SICUS), and Ileocolonoscopy. Methods We prospectively enrolled 40 consecutive patients (22 male, 18 female, mean age 13.1 ± 3.1 years) with CD of the small bowel and colon. All underwent SICUS, MRE, CCE, and Ileocolonoscopy sequentially over 5 days. All investigators were blinded to patient history and test results. Patients were classified as active or inactive for the small bowel and the colon according to specific criteria for each tool (simple endoscopic score for CD, Lewis score, US and magnetic resonance parameters of activity). For colon mucosa evaluation, Ileocolonoscopy was the comparator. For the small bowel, a consensus panel was convened. Results Sensitivity of CCE to detect colon inflammation was 89%, and specificity was 100%. The positive predictive value (PPV) and negative predictive value (NPV) of CCE for colon inflammation were 100% and 91%, respectively. In the small bowel, CCE showed 90% sensitivity, 94% specificity, with PPV and NPV of 95% and 90%, respectively. Accuracy parameters for SICUS (sensitivity 90%, specificity 83%) and MRE (sensitivity 85%, specificity 89%) were lower than those for CCE. No serious adverse events related to the CCE procedure or preparation were reported. Conclusions CCE is of great usefulness in evaluating both small bowel and colon mucosa in pediatric CD. This single, noninvasive tool makes it possible to evaluate the small-bowel and the colon concurrently with high diagnostic accuracy. Future multicenter studies need to define the role of CCE in the routine management of pediatric patients with CD. (Clinical trial registration number: NCT02199626.)
William J Sandborn - One of the best experts on this subject based on the ideXlab platform.
-
magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with crohn s disease and may help select subjects with active inflammation
2016Co-Authors: Alexandre Coimbra, Jeff L Fidler, David H Bruining, J. Rimola, T. Bengtsson, A. De Crespigny, D. Luca, P. Rutgeerts, Sharon Obyrne, William J SandbornAbstract:Summary Background Reliable tools for patient selection are critical for clinical drug trials. Aim To evaluate a consensus-based, standardised magnetic resonance enterography (MRE) protocol for selecting patients for inclusion in Crohn's disease (CD) multicenter clinical trials. Methods This study recruited 20 patients [Crohn's Disease Activity Index (CDAI) scores: <150 (n = 8); 150–220 (n = 4); 220–450 (n = 8)], to undergo Ileocolonoscopy and two MREs (with and without colonic contrast) within a 14-day period. Procedures were scored centrally using, Magnetic Resonance Index of Activity (MaRIA), and both Crohn's Disease Endoscopic Index of Severity (CDEIS) and Simplified Endoscopic Score (SES-CD). Results 37 MREs were acquired. Both MREs were evaluable in 16 patients for calculation of test–retest and inter-reader reliability scores. The MaRIA scores for the terminal ileum had excellent test–retest and inter-reader reliability, with correlations >0.9. The proximal ileum showed strong within-reader agreement (0.90–0.96), and fair between-reader agreement (0.59–0.72). MRE procedures were tolerable. MaRIA scores correlated with CDEIS and SES-CD (0.63 and 0.71), but not with CDAI (0.34). MRE identified 3 patients with intra-abdominal complications, who would otherwise have been included in clinical trials. Furthermore, both MRE and Ileocolonoscopy identified active bowel wall inflammation in 2 patients with CDAI 220. Data quality was good/excellent in 85% of scans, and fair or better in 96%. Conclusions Magnetic resonance enterography of high-quality and reproducibility was feasible in a global multi- centre setting, with evidence for improved selectivity over CDAI and Ileocolonoscopy in identifying appropriate CD patients for inclusion in therapeutic intervention trials.
-
selecting therapeutic targets in inflammatory bowel disease stride determining therapeutic goals for treat to target
2015Co-Authors: Laurent Peyrinbiroulet, William J Sandborn, Walter Reinisch, Bruce E Sands, Willem A Bemelman, Robert V Bryant, G Dhaens, Iris Dotan, Marla DubinskyAbstract:OBJECTIVES: The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a "treat-to-target" clinical management strategy using an evidence-based expert consensus process. METHODS: A Steering Committee of 28 IBD specialists developed recommendations based on a systematic literature review and expert opinion. Consensus was gained if >= 75% of participants scored the recommendation as 7-10 on a 10-point rating scale (where 10=agree completely). RESULTS: The group agreed upon 12 recommendations for ulcerative colitis (UC) and Crohn's disease (CD). The agreed target for UC was clinical/patient-reported outcome (PRO) remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as a Mayo endoscopic subscore of 0-1). Histological remission was considered as an adjunctive goal. Clinical/PRO remission was also agreed upon as a target for CD and defined as resolution of abdominal pain and diarrhea/altered bowel habit; and endoscopic remission, defined as resolution of ulceration at Ileocolonoscopy, or resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with Ileocolonoscopy. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target. CONCLUSIONS: Evidence-and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available. Prospective studies are needed to determine how these targets will change disease course and patients' quality of life.
-
clinical disease activity c reactive protein normalisation and mucosal healing in crohn s disease in the sonic trial
2014Co-Authors: Laurent Peyrinbiroulet, Paul Rutgeerts, Jean-frederic Colombel, Walter Reinisch, Gerassimos J Mantzaris, Asher Kornbluth, Robert H Diamond, Linda K Tang, Freddy Cornillie, William J SandbornAbstract:Background and aims The Crohn9s Disease Activity Index (CDAI) has been criticised due to heavy weighting on subjective clinical symptoms. C-reactive protein (CRP) and endoscopic lesions are objective measures of inflammation. We investigated the relationships between clinical disease activity, CRP normalisation and mucosal healing in Crohn9s disease (CD). Methods The Study of Biologic and Immunomodulator Naive Patients in CD trial compared infliximab to azathioprine and to infliximab plus azathioprine in 508 CD patients. Mucosal healing was defined as the absence of mucosal ulceration at the week 26 Ileocolonoscopy in a patient who had evidence of ulceration at the baseline Ileocolonoscopy. Results 188 patients who had evaluable Ileocolonoscopy with evidence of mucosal ulceration at baseline, CDAI scores and CRP values at baseline and week 26 were analysed. Seventy-two of 136 patients (53%) who had a CDAI Conclusions Half the patients under azathioprine and/or infliximab in clinical remission have endoscopic and/or CRP evidence of residual active CD, whereas other patients with endoscopic and CRP normalisation have persistent clinical symptoms. Clinical symptoms as scored by CDAI are not a reliable measure of the underlying inflammation.
-
endoscopic skipping of the distal terminal ileum in crohn s disease can lead to negative results from Ileocolonoscopy
2012Co-Authors: David H Bruining, Edward V Loftus, Jayawant N Mandrekar, Joel G Fletcher, Alan R Zinsmeister, Sunil Samuel, Brenda D Becker, William J SandbornAbstract:Background & Aims Crohn's disease often involves the terminal ileum (TI), but skipping of the distal TI can occur. This can lead to negative results from Ileocolonoscopy. We analyzed advanced cross-sectional images to determine how frequently this occurs. Methods We analyzed data from 189 consecutive patients (55% women) with Crohn's disease, evaluated in 2009 by computed tomography enterography (CTE) and Ileocolonoscopy. The discharge impression of the gastroenterologist who treated the patients was used as the reference standard for Crohn's disease activity. Results Of the patients evaluated, 153 underwent TI intubation during endoscopy; 67 of these (43.8%) had normal results from ileoscopy, based on endoscopic appearance. Despite their normal results from ileoscopy, 36 of these patients (53.7%) had active, small-bowel Crohn's disease. The ileum appeared normal at ileoscopy because the disease had skipped the distal ileum of 11 patients (30.6%), developed only in the intramural and mesenteric distal ileum of 23 patients (63.9%), and appeared only in the upper gastrointestinal region of 2 patients (5.6%). These patients had a shorter duration of disease (61.1% for less than 5 years) compared with those found to have Crohn's disease based on ileoscopy (41.1% for less than 5 years; P Conclusions Ileoscopy examination can miss Crohn's disease of the TI because the disease can skip the distal ileum or is confined to the intramural portion of the bowel wall and the mesentery. CTE complements Ileocolonoscopy in assessing disease activity in patients with Crohn's disease.
-
validation of a lower radiation computed tomography enterography imaging protocol to detect crohn s disease in the small bowel
2011Co-Authors: Hassan Siddiki, Jeff L Fidler, James E Huprich, William J Sandborn, Joel G Fletcher, Amy K Hara, James M Kofler, Cynthia H Mccollough, Luis S Guimaraes, Edward V LoftusAbstract:Background: The purpose was to validate a lower radiation dose computed tomography enterography (CTE) imaging protocol to detect the presence of Crohn's disease (CD) in the small bowel using two different reference standards and to identify a prediction model based on CTE signs for the presence of active CD. Methods: This retrospective study included patients with known or suspected CD who underwent CTE between January and October 2006 according to a lower radiation dose protocol. Two gastrointestinal radiologists blindly and independently classified each CTE as being active or inactive. Reference standards included Ileocolonoscopy ± biopsy and a comprehensive clinical reference standard (retrospectively created by a gastroenterologist, also including history, physical, follow-up course, and subsequent endoscopy, imaging, or surgery). Logistic regression was used to identify CTE findings that predicted the presence of active CD based on the combined clinical reference standard. Results: In all, 137 patients underwent CTE and Ileocolonoscopy. Using an endoscopic reference standard, the sensitivity of CTE to detect active CD for the two readers was 81% and 89%, respectively. Using the clinical reference standard, the sensitivity of CTE to detect active CD was 89% and 98%, respectively. For both readers the sensitivity of CTE increased by 8%–9% when using the comprehensive reference standard. Multivariate analysis showed that a combination of mural thickness and hyperenhancement best predicted active CD (area under the curve [AUC] = 0.92–0.93, P < 0.0001). Conclusions: Lower radiation dose CTE exams are sensitive for the detection of active small bowel CD. The combination of mural thickness and hyperenhancement are the best radiologic predictors of active CD. (Inflamm Bowel Dis 2011;)
Andrea Tringali - One of the best experts on this subject based on the ideXlab platform.
-
paediatric gastrointestinal endoscopy european society for paediatric gastroenterology hepatology and nutrition and european society of gastrointestinal endoscopy guidelines
2017Co-Authors: Mike Thomson, Cesare Hassan, Andrea Tringali, Jeanmarc Dumonceau, Marta Tavares, Merit M Tabbers, Raoul I Furlano, Manon C W Spaander, Christos Tzvinikos, Hanneke IjsselstijnAbstract:This guideline refers to infants, children, and adolescents ages 0 to 18 years. The areas covered include indications for diagnostic and therapeutic esophagogastroduodenoscopy and Ileocolonoscopy; endoscopy for foreign body ingestion; corrosive ingestion and stricture/stenosis endoscopic management; upper and lower gastrointestinal bleeding; endoscopic retrograde cholangiopancreatography; and endoscopic ultrasonography. Percutaneous endoscopic gastrostomy and endoscopy specific to inflammatory bowel disease has been dealt with in other guidelines and are therefore not mentioned in this guideline. Training and ongoing skill maintenance are to be dealt with in an imminent sister publication to this.
-
pediatric gastrointestinal endoscopy european society of gastrointestinal endoscopy esge and european society for paediatric gastroenterology hepatology and nutrition espghan guideline executive summary
2016Co-Authors: Andrea Tringali, Mike Thomson, Cesare Hassan, Jeanmarc Dumonceau, Marta Tavares, Merit M Tabbers, Raoul I Furlano, Manon C W Spaander, Christos Tzvinikos, Hanneke IjsselstijnAbstract:This Executive summary of the Guideline on pediatric gastrointestinal endoscopy from the European Society of Gastrointestinal Endoscopy (ESGE) and the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) refers to infants, children, and adolescents aged 0 – 18 years. The areas covered include: indications for diagnostic and therapeutic esophagogastroduodenoscopy and Ileocolonoscopy; endoscopy for foreign body ingestion; endoscopic management of corrosive ingestion and stricture/stenosis; upper and lower gastrointestinal bleeding; endoscopic retrograde cholangiopancreatography, and endoscopic ultrasonography. Percutaneous endoscopic gastrostomy and endoscopy specific to inflammatory bowel disease (IBD) have been dealt with in other Guidelines and are therefore not mentioned in this Guideline. Training and ongoing skill maintenance will be addressed in an imminent sister publication.
